Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boundless Bio, Inc. (BOLD)
USD2.49
+0.03 (+1.02%)
US NASDAQ Healthcare Biotechnology
Address
9880 Campus Point Drive 92121
San Diego, CA, US
San Diego, CA, US
CEO
Zachary Hornby
Website
boundlessbio.com
IPO
2016-07-20
CIK 1782303 ISIN US10170A1007
Description
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.49
+0.03 (+1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.97
Float Shares
17.17M
Free Float %
76.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.23% | -5.66% | +32.74% | +32.74% | +21.95% | +25.00% | +0.67% | -89.47% | -89.47% | -89.47% | -89.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (20 ratings, all time)
Hold
Price Targets & DCF
Current price
2.49
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.98
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+32.5% ★ Q1'26: +15.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-158.5% Q1'26: -138.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+31.7% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.79× Q1'26: -0.85× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
8.40M
8.40M – 8.40M
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-64.28M
|
-62.30M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-65.36M
|
-63.55M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-65.36M
est: -65.69M (+0.5%)
|
-58.20M
est: -55.23M (-5.4%)
|
-53.22M
-53.22M – -53.22M
+3.6% YoY
|
-28.62M
-28.62M – -28.62M
+46.2% YoY
|
-24.48M
-24.48M – -24.48M
+14.5% YoY
|
-29.96M
-29.96M – -29.96M
-22.4% YoY
|
-31.30M
-31.30M – -31.30M
-4.5% YoY
|
| SGA |
18.00M
|
18.71M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.85
est: -3.83 (-0.5%)
|
-2.60
est: -2.47 (-5.3%)
|
-2.38
-2.38 – -2.38
+3.6% YoY
|
-1.28
-1.28 – -1.28
+46.2% YoY
|
-1.10
-1.10 – -1.10
+14.5% YoY
|
-1.34
-1.34 – -1.34
-22.4% YoY
|
-1.40
-1.40 – -1.40
-4.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
847.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 3.26M | 14.67% | — | — | 3.26M | — | IN | Delaware | 2024-04-10 | ↗ |
| 2 | FMR LLC | 3.26M | 14.67% | 3.26M | — | 3.26M | — | HC | Delaware | 2024-04-10 | ↗ |
| 3 | Kristina Burow | 2.70M | 12.10% | 5.9K | 2.69M | 5.9K | 2.69M | IN | States | 2024-10-29 | ↗ |
| 4 | ARCH Venture Fund IX Overage, L.P. | 2.69M | 12.10% | — | 2.69M | — | 2.69M | PN | Delaware | 2024-10-29 | ↗ |
| 5 | ARCH Venture Fund IX, L.P. | 2.69M | 12.10% | — | 2.69M | — | 2.69M | PN | Delaware | 2024-10-29 | ↗ |
| 6 | ARCH Venture Fund X Overage, L.P. | 2.69M | 12.10% | — | 2.69M | — | 2.69M | PN | Delaware | 2024-10-29 | ↗ |
| 7 | ARCH Venture Partners IX Overage, L.P. | 2.69M | 12.10% | — | 2.69M | — | 2.69M | PN | Delaware | 2024-10-29 | ↗ |
| 8 | ARCH Venture Partners IX, L.P. | 2.69M | 12.10% | — | 2.69M | — | 2.69M | PN | Delaware | 2024-10-29 | ↗ |
| 9 | ARCH Venture Partners X Overage, L.P. | 2.69M | 12.10% | — | 2.69M | — | 2.69M | PN | Delaware | 2024-10-29 | ↗ |
| 10 | ARCH Venture Partners X, LLC | 2.69M | 12.10% | — | 2.69M | — | 2.69M | OO | Delaware | 2024-10-29 | ↗ |
| 11 | Clinton Bybee | 2.69M | 12.10% | — | 2.69M | — | 2.69M | IN | States | 2024-10-29 | ↗ |
| 12 | Keith Crandell | 2.69M | 12.10% | — | 2.69M | — | 2.69M | IN | States | 2024-10-29 | ↗ |
| 13 | Robert Nelsen | 2.69M | 12.10% | — | 2.69M | — | 2.69M | IN | States | 2024-10-29 | ↗ |
| 14 | Steven Gillis | 2.69M | 12.10% | — | 2.69M | — | 2.69M | IN | States | 2024-10-29 | ↗ |
| 15 | Peter Kolchinsky | 2.18M | 9.80% | — | 2.18M | — | 2.18M | HC, IN | Delaware | 2024-04-12 | ↗ |
| 16 | RA Capital Management, L.P. | 2.18M | 9.80% | — | 2.18M | — | 2.18M | IA, PN | Delaware | 2024-04-12 | ↗ |
| 17 | Rajeev Shah | 2.18M | 9.80% | — | 2.18M | — | 2.18M | HC, IN | Delaware | 2024-04-12 | ↗ |
| 18 | RA Capital Healthcare Fund, L.P. | 1.88M | 8.50% | — | 1.88M | — | 1.88M | PN | Delaware | 2024-04-12 | ↗ |
| 19 | Bayer Aktiengesellschaft | 1.62M | 7.30% | — | — | — | 1.62M | HC, CO | Citizenship or Place of Organization | 2024-04-09 | ↗ |
| 20 | Bayer HealthCare LLC | 1.62M | 7.30% | — | — | — | 1.62M | CO | Citizenship or Place of Organization | 2024-04-09 | ↗ |
| 21 | Bayer US Holding LP | 1.62M | 7.30% | — | — | — | 1.62M | PN | Citizenship or Place of Organization | 2024-04-09 | ↗ |
| 22 | Bayer World Investments B.V. | 1.62M | 7.30% | — | — | — | 1.62M | CO | Citizenship or Place of Organization | 2024-04-09 | ↗ |
| 23 | Costas Constantinides | 1.23M | 5.50% | — | 1.23M | — | — | IN | Luxembourg | 2024-04-12 | ↗ |
| 24 | Ian Charoub | 1.23M | 5.50% | — | 1.23M | — | — | IN | Luxembourg | 2024-04-12 | ↗ |
| 25 | Nextech VI GP S.à. r.l. | 1.23M | 5.50% | 1.23M | — | 1.23M | — | OO | Luxembourg | 2024-04-12 | ↗ |
| 26 | Nextech VI Oncology SCSp | 1.23M | 5.50% | 1.23M | — | 1.23M | — | PN | Luxembourg | 2024-04-12 | ↗ |
| 27 | Rocco Sgobbo | 1.23M | 5.50% | — | 1.23M | — | — | IN | Luxembourg | 2024-04-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-28 vs prev Q
New positions
5
Closed positions
33
Increased
6
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 2.68M -414.0K (-13.4%) | 3.22M -589.8K (-15.5%) | 11.99% -1.868 pp | 0.00% +0.000 pp | USD13.31 -91.0% | 8 qtrs — |
| 2 | CITADEL ADVISORS LLC | 1.35M +477.5K (+54.5%) | 1.62M +546.7K (+50.7%) | 6.05% +2.128 pp | 0.00% +0.000 pp | USD7.85 -84.7% | 8 qtrs — |
| 3 | STONEPINE CAPITAL MANAGEMENT, LLC | 710.1K +296.6K (+71.7%) | 852.1K +343.5K (+67.6%) | 3.17% +1.323 pp | 0.62% +0.209 pp | USD1.18 +1.7% | 3 qtrs — |
| 4 | SECTORAL ASSET MANAGEMENT INC | 678.6K +— (+0.0%) | 814.3K -20.4K (-2.4%) | 3.03% -0.004 pp | 0.65% +0.138 pp | USD13.54 -91.1% | 8 qtrs — |
| 5 | VANGUARD GROUP INC | 662.8K +93.1K (+16.3%) | 795.3K +94.6K (+13.5%) | 2.96% +0.413 pp | 0.00% +0.000 pp | USD2.97 -59.6% | 8 qtrs — |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 556.2K +— (+0.0%) | 667.5K -16.7K (-2.4%) | 2.48% -0.003 pp | 0.00% +0.000 pp | USD13.54 -91.1% | 8 qtrs — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 341.4K +117.8K (+52.7%) | 409.7K +134.7K (+49.0%) | 1.53% +0.525 pp | 0.00% +0.000 pp | USD1.16 +3.4% | 7 qtrs — |
| 8 | ALYESKA INVESTMENT GROUP, L.P. | 300.0K +— (+0.0%) | 360.0K -9.0K (-2.4%) | 1.34% -0.002 pp | 0.00% 0.000 pp | USD11.98 -90.0% | 8 qtrs — |
| 9 | RBF CAPITAL, LLC | 200.0K +— (+0.0%) | 240.0K -6.0K (-2.4%) | 0.89% -0.001 pp | 0.01% 0.000 pp | USD1.01 +18.8% | 3 qtrs — |
| 10 | NORTHERN TRUST CORP | 189.5K -1.3K (-0.7%) | 227.4K -7.3K (-3.1%) | 0.85% -0.007 pp | 0.00% +0.000 pp | USD2.05 -41.5% | 6 qtrs — |
| 11 | ENSIGN PEAK ADVISORS, INC | 187.5K +— (+0.0%) | 225.0K -5.6K (-2.4%) | 0.84% -0.001 pp | 0.00% +0.000 pp | USD13.54 -91.1% | 8 qtrs — |
| 12 | SIO CAPITAL MANAGEMENT, LLC | 163.7K +— (+0.0%) | 196.4K -4.9K (-2.4%) | 0.73% -0.001 pp | 0.03% -0.020 pp | USD12.33 -90.3% | 8 qtrs — |
| 13 | MILLENNIUM MANAGEMENT LLC | 135.4K -28.7K (-17.5%) | 162.5K -39.3K (-19.5%) | 0.60% -0.129 pp | 0.00% +0.000 pp | USD1.01 +18.8% | 3 qtrs — |
| 14 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 127.6K +127.6K (+100.0%) | 153.2K +153.2K (+100.0%) | 0.57% +0.570 pp | 0.01% +0.010 pp | USD1.20 +0.0% | 1 qtrs NEW |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 94.1K -8.2K (-8.0%) | 112.9K -12.9K (-10.2%) | 0.42% -0.037 pp | 0.00% +0.000 pp | USD2.50 -52.0% | 7 qtrs — |
| 16 | BLACKROCK, INC. | 67.0K +1.7K (+2.6%) | 80.5K +47.0 (+0.1%) | 0.30% +0.007 pp | 0.00% +0.000 pp | USD3.17 -62.1% | 6 qtrs — |
| 17 | GSA CAPITAL PARTNERS LLP | 62.5K +62.5K (+100.0%) | 75.0K +75.0K (+100.0%) | 0.28% +0.279 pp | 0.01% +0.007 pp | USD1.20 +0.0% | 1 qtrs NEW |
| 18 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 50.5K +— (+0.0%) | 60.6K -1.5K (-2.4%) | 0.23% 0.000 pp | 0.00% 0.000 pp | USD1.01 +18.8% | 6 qtrs — |
| 19 | WALLEYE CAPITAL LLC | 39.6K +— (+0.0%) | 47.5K -1.2K (-2.4%) | 0.18% 0.000 pp | 0.00% +0.000 pp | USD4.19 -71.4% | 7 qtrs — |
| 20 | XTX TOPCO LTD | 39.6K +10.5K (+36.1%) | 47.5K +11.7K (+32.8%) | 0.18% +0.047 pp | 0.00% -0.001 pp | USD1.30 -7.7% | 4 qtrs — |
| 21 | CITIGROUP INC | 25.1K +25.1K (+100.0%) | 30.1K +30.1K (+100.0%) | 0.11% +0.112 pp | 0.00% +0.000 pp | USD1.20 +0.0% | 7 qtrs — |
| 22 | QUBE RESEARCH & TECHNOLOGIES LTD | 18.7K +660.0 (+3.7%) | 22.4K +250.0 (+1.1%) | 0.08% +0.003 pp | 0.00% +0.000 pp | USD1.02 +17.6% | 3 qtrs — |
| 23 | STATE STREET CORP | 16.0K +— (+0.0%) | 19.2K -479.0 (-2.4%) | 0.07% 0.000 pp | 0.00% +0.000 pp | USD3.40 -64.7% | 7 qtrs — |
| 24 | JANE STREET GROUP, LLC | 13.3K +13.3K (+100.0%) | 16.0K +16.0K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.000 pp | USD1.20 +0.0% | 1 qtrs NEW |
| 25 | MORGAN STANLEY | 13.0K -2.5K (-16.1%) | 15.6K -3.5K (-18.2%) | 0.06% -0.011 pp | 0.00% +0.000 pp | USD3.69 -67.5% | 7 qtrs — |
| 26 | ABEL HALL, LLC | 12.9K -60.0 (-0.5%) | 15.4K -460.0 (-2.9%) | 0.06% 0.000 pp | 0.00% -0.003 pp | USD1.01 +18.8% | 3 qtrs — |
| 27 | ACADIAN ASSET MANAGEMENT LLC | 12.6K -1.1K (-8.3%) | 14.0K -2.0K (-12.5%) | 0.06% -0.005 pp | 0.00% +0.000 pp | USD2.90 -58.6% | 5 qtrs — |
| 28 | — | 11.3K +11.3K (+100.0%) | 13.6K +13.6K (+100.0%) | 0.05% +0.051 pp | 0.01% +0.008 pp | USD1.20 +0.0% | 1 qtrs NEW |
| 29 | BANK OF AMERICA CORP /DE/ | 7.8K +19.0 (+0.2%) | 9.3K -209.0 (-2.2%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD3.60 -66.7% | 7 qtrs — |
| 30 | TOWER RESEARCH CAPITAL LLC (TRC) | 5.8K +3.2K (+123.8%) | 7.0K +3.8K (+118.4%) | 0.03% +0.014 pp | 0.00% +0.000 pp | USD2.00 -40.0% | 7 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 176.00 -173.0 (-49.6%) | 211.00 -218.0 (-50.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.48 -65.5% | 7 qtrs — |
| 32 | JPMORGAN CHASE & CO | 169.00 +169.0 (+100.0%) | 203.00 +203.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.20 +0.0% | 7 qtrs — |
| 33 | OPTIVER HOLDING B.V. | 168.00 +— (+0.0%) | 202.00 -5.0 (-2.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.23 -2.4% | 2 qtrs — |
| 34 | UBS GROUP AG | 23.00 +22.0 (+2,200.0%) | 27.00 +26.0 (+2,600.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.26 -4.8% | 7 qtrs — |
| 35 | BARCLAYS PLC | 2.00 -8.6K (-100.0%) | 2.00 -30.0K (-100.0%) | 0.00% -0.039 pp | 0.00% +0.000 pp | USD1.00 +20.0% | 8 qtrs — |
| 36 | SQUAREPOINT OPS LLC | — -50.8K (-100.0%) | — -62.4K (-100.0%) | 0.00% -0.227 pp | 0.00% 0.000 pp | USD— | 8 qtrs SOLD |
| 37 | REDMILE GROUP, LLC | — -245.5K (-100.0%) | — -301.9K (-100.0%) | 0.00% -1.098 pp | 0.00% -0.029 pp | USD— | 8 qtrs SOLD |
| 38 | ALMITAS CAPITAL LLC | — -86.8K (-100.0%) | — -106.8K (-100.0%) | 0.00% -0.388 pp | 0.00% -0.024 pp | USD— | 5 qtrs SOLD |
| 39 | NEXTECH INVEST, LTD. | — -1.2M (-100.0%) | — -1.5M (-100.0%) | 0.00% -5.493 pp | 0.00% -0.230 pp | USD— | 4 qtrs SOLD |
| 40 | GOLDMAN SACHS GROUP INC | — -14.3K (-100.0%) | — -17.6K (-100.0%) | 0.00% -0.064 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 141.8K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 215.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.4K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.8K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 277.47 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 641.9K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.4K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 765.77 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 309.55 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 34.08 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
104.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+104,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 | Oien Jessica | Officer | A-Award | A | Stock Option (right to buy) | 220,000 | 1.26 | 277.2K | 220,000 | D | ↗ |
| 2026-01-23 | Hornby Zachary | Director / Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 1.26 | 756.0K | 600,000 | D | ↗ |
| 2026-01-23 | Hassig Christian | Officer | A-Award | A | Stock Option (right to buy) | 230,000 | 1.26 | 289.8K | 230,000 | D | ↗ |
| 2026-01-23 | HINKLE DAVID A | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 1.26 | 176.4K | 140,000 | D | ↗ |
| 2026-01-23 | Doebele Robert | Officer | A-Award | A | Stock Option (right to buy) | 230,000 | 1.26 | 289.8K | 230,000 | D | ↗ |
| 2025-06-23 | Whiting Nancy | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 1.03 | 16.5K | 16,000 | D | ↗ |
| 2025-06-23 | Lim Jonathan E | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 1.03 | 24.7K | 24,000 | D | ↗ |
| 2025-06-23 | Lew Jennifer | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 1.03 | 16.5K | 16,000 | D | ↗ |
| 2025-06-23 | Christensen James | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 1.03 | 16.5K | 16,000 | D | ↗ |
| 2025-06-23 | Burow Kristina | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 16,000 | 1.03 | 16.5K | 16,000 | D | ↗ |
| 2025-06-23 | Brennan Christine | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 1.03 | 16.5K | 16,000 | D | ↗ |
| 2020-01-15 | Soloway Thomas P | Officer | D-Return | D | Stock Option (Right to Buy) | 65,000 | 24.74 | 1.61M | 0 | — | ↗ |
| 2020-01-15 | Patterson Matthew R | Director / Officer | U-Tender | D | Common Stock | 171,814 | 60.00 | 10.31M | 0 | — | ↗ |
| 2020-01-15 | Holles Natalie C. | Officer | D-Return | D | Stock Option (Right to Buy) | 25,000 | 36.39 | 909.8K | 0 | — | ↗ |
| 2020-01-15 | Goldberg Mark Alan | Director | D-Return | D | Stock Option (Right to Buy) | 10,000 | 38.65 | 386.5K | 0 | — | ↗ |
| 2020-01-15 | Conner Edward R. | Officer | U-Tender | D | Common Stock | 24,584 | 60.00 | 1.48M | 0 | — | ↗ |
| 2020-01-08 | Soloway Thomas P | Officer | M-Exempt | D | Stock Option (right to buy) | 144,669 | 2.76 | 400.0K | 3,829 | — | ↗ |
| 2020-01-08 | Patterson Matthew R | Director / Officer | M-Exempt | A | Common Stock | 74,297 | 2.19 | 162.7K | 237,968 | — | ↗ |
| 2019-12-26 | Patterson Matthew R | Director / Officer | G-Gift | D | Common Stock | 12,500 | 0.00 | — | 98,920 | — | ↗ |
| 2019-12-12 | Soloway Thomas P | Officer | F-InKind | D | Common Stock | 8,681 | 59.37 | 515.4K | 12,633 | — | ↗ |
| 2019-12-12 | Holles Natalie C. | Officer | F-InKind | D | Common Stock | 88,928 | 59.37 | 5.28M | 104,439 | — | ↗ |
| 2019-12-12 | Conner Edward R. | Officer | F-InKind | D | Common Stock | 5,416 | 59.37 | 321.5K | 24,584 | — | ↗ |
| 2019-12-05 | Soloway Thomas P | Officer | F-InKind | D | Common Stock | 505 | 59.21 | 29.9K | 21,314 | — | ↗ |
| 2019-12-05 | Patterson Matthew R | Director / Officer | F-InKind | D | Common Stock | 1,974 | 59.21 | 116.9K | 111,420 | — | ↗ |
| 2019-12-05 | Holles Natalie C. | Officer | F-InKind | D | Common Stock | 505 | 59.21 | 29.9K | 54,704 | — | ↗ |
| 2019-11-08 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 14,426 | 9.50 | 137.0K | 155,393 | — | ↗ |
| 2019-09-05 | Soloway Thomas P | Officer | F-InKind | D | Common Stock | 505 | 31.02 | 15.7K | 21,819 | — | ↗ |
| 2019-09-05 | Patterson Matthew R | Director / Officer | F-InKind | D | Common Stock | 1,974 | 31.02 | 61.2K | 113,394 | — | ↗ |
| 2019-09-05 | Holles Natalie C. | Officer | F-InKind | D | Common Stock | 505 | 31.02 | 15.7K | 55,209 | — | ↗ |
| 2019-08-12 | Patterson Matthew R | Director / Officer | S-Sale | D | Common Stock | 19,000 | 34.02 | 646.3K | 116,368 | — | ↗ |
| 2019-07-15 | Conner Edward R. | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 36.08 | 3.25M | 90,000 | — | ↗ |
| 2019-06-05 | Soloway Thomas P | Officer | F-InKind | D | Common Stock | 1,009 | 37.31 | 37.6K | 22,324 | — | ↗ |
| 2019-06-05 | Patterson Matthew R | Director / Officer | F-InKind | D | Common Stock | 3,332 | 37.31 | 124.3K | 115,368 | — | ↗ |
| 2019-06-05 | Holles Natalie C. | Officer | F-InKind | D | Common Stock | 1,009 | 37.31 | 37.6K | 55,714 | — | ↗ |
| 2019-02-25 | Patterson Matthew R | Director / Officer | M-Exempt | A | Common Stock | 17,000 | 0.78 | 13.3K | 135,700 | — | ↗ |
| 2019-02-06 | Soloway Thomas P | Officer | A-Award | A | Common Stock | 23,333 | 0.00 | — | 23,333 | — | ↗ |
| 2019-02-06 | Patterson Matthew R | Director / Officer | A-Award | A | Common Stock | 63,700 | 0.00 | — | 118,700 | — | ↗ |
| 2019-02-06 | Holles Natalie C. | Officer | A-Award | A | Common Stock | 23,333 | 0.00 | — | 56,723 | — | ↗ |
| 2019-02-06 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 16,200 | 24.74 | 400.8K | 16,200 | — | ↗ |
| 2019-01-24 | Holles Natalie C. | Officer | M-Exempt | D | Stock Option (right to buy) | 8,300 | 2.76 | 22.9K | 156,429 | — | ↗ |
| 2018-12-06 | Patterson Matthew R | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 0.78 | 31.2K | 55,000 | — | ↗ |
| 2018-10-01 | Patterson Matthew R | Director / Officer | M-Exempt | A | Common Stock | 2,144 | 0.78 | 1.7K | 17,144 | — | ↗ |
| 2018-09-24 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 15,000 | 0.78 | 11.7K | 92,702 | — | ↗ |
| 2018-09-18 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 12,952 | 2.19 | 28.4K | 128,345 | — | ↗ |
| 2018-07-05 | Patterson Matthew R | Director / Officer | S-Sale | D | Common Stock | 23,147 | 40.04 | 926.9K | 0 | — | ↗ |
| 2018-07-03 | Patterson Matthew R | Director / Officer | S-Sale | D | Common Stock | 26,901 | 40.05 | 1.08M | 0 | — | ↗ |
| 2018-07-02 | Patterson Matthew R | Director / Officer | M-Exempt | A | Common Stock | 1,401 | 0.78 | 1.1K | 1,401 | — | ↗ |
| 2018-06-08 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 38.65 | 386.5K | 10,000 | — | ↗ |
| 2018-06-01 | Holles Natalie C. | Officer | M-Exempt | D | Stock Option (right to buy) | 5,090 | 2.76 | 14.1K | 164,729 | — | ↗ |
| 2018-05-21 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 20,300 | 0.78 | 15.8K | 178,750 | — | ↗ |
| 2018-05-07 | Holles Natalie C. | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 36.39 | 909.8K | 25,000 | — | ↗ |
| 2018-04-02 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 700 | 0.78 | 546.00 | 199,050 | — | ↗ |
| 2018-03-12 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 16,937 | 34.92 | 591.4K | 3,539,997 | — | ↗ |
| 2018-03-09 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 21,300 | 34.67 | 738.5K | 3,616,700 | — | ↗ |
| 2018-03-08 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 58,428 | 34.06 | 1.99M | 3,638,000 | — | ↗ |
| 2018-03-06 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 11,372 | 33.03 | 375.6K | 3,696,428 | — | ↗ |
| 2018-03-05 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 200 | 36.06 | 7.2K | 3,707,800 | — | ↗ |
| 2018-03-02 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 386,080 | 35.06 | 13.54M | 3,743,558 | — | ↗ |
| 2018-01-18 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 4,500 | 38.00 | 171.0K | 4,500 | — | ↗ |
| 2018-01-01 | Goldberg Mark Alan | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 33.91 | 610.4K | 18,000 | — | ↗ |
| 2017-12-11 | Goldberg Mark Alan | Director | — | D | Common Stock | 0 | 0.00 | — | 1,500 | — | ↗ |
| 2017-11-16 | Soloway Thomas P | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 27.39 | 2.05M | 75,000 | — | ↗ |
| 2017-11-16 | Patterson Matthew R | Director / Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 27.39 | 6.16M | 225,000 | — | ↗ |
| 2017-11-16 | Holles Natalie C. | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 27.39 | 2.74M | 100,000 | — | ↗ |
| 2017-10-02 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 0.78 | 7.8K | 199,750 | — | ↗ |
| 2017-09-29 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 672,000 | 28.25 | 18.98M | 4,129,638 | — | ↗ |
| 2017-09-18 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 8,458 | 0.78 | 6.6K | 209,750 | — | ↗ |
| 2017-09-15 | Patterson Matthew R | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 1,542 | 0.78 | 1.2K | 218,208 | — | ↗ |
| 2017-09-07 | ORBIMED ADVISORS LLC | 10% Owner | X-InTheMoney | A | Common Stock | 5,000 | 15.03 | 75.2K | 4,806,638 | — | ↗ |
| 2017-07-13 | Patterson Matthew R | Director / Officer | S-Sale | D | Common Stock | 12,150 | 20.00 | 243.1K | 186,814 | — | ↗ |
| 2017-07-12 | Patterson Matthew R | Director / Officer | S-Sale | D | Common Stock | 2,850 | 20.00 | 57.0K | 198,964 | — | ↗ |
| 2017-05-31 | Holles Natalie C. | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 2.76 | 55.2K | 169,819 | — | ↗ |
| 2017-04-24 | 5AM Partners III, LLC | 10% Owner | P-Purchase | A | Common Stock | 168,082 | 14.50 | 2.44M | 2,500,113 | — | ↗ |
| 2017-01-25 | Soloway Thomas P | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 15.26 | 1.22M | 80,000 | — | ↗ |
| 2017-01-25 | Patterson Matthew R | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 15.26 | 3.05M | 200,000 | — | ↗ |
| 2017-01-25 | Holles Natalie C. | Officer | A-Award | A | Stock Option (right to buy) | 115,000 | 15.26 | 1.75M | 115,000 | — | ↗ |
| 2016-08-24 | Woiwode Thomas | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 15.03 | 270.5K | 18,000 | — | ↗ |
| 2016-08-24 | SILVERSTEIN JONATHAN | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 18,000 | 15.03 | 270.5K | 18,000 | — | ↗ |
| 2016-07-25 | Woiwode Thomas | Director | C-Conversion | D | Series A Preferred Stock | 6,811 | 0.00 | — | 0 | — | ↗ |
| 2016-07-25 | SILVERSTEIN JONATHAN | Director / 10% Owner | C-Conversion | D | Series C Preferred Stock | 332,766 | 0.00 | — | 0 | — | ↗ |
| 2016-07-25 | ORBIMED ADVISORS LLC | Director / 10% Owner | C-Conversion | D | Series Seed Preferred Stock | 627,867 | 0.00 | — | 0 | — | ↗ |
| 2016-07-25 | Flynn James E | 10% Owner | C-Conversion | D | Series C Convertible Preferred Stock | 99,830 | 0.00 | — | 0 | — | ↗ |
| 2016-07-19 | Woiwode Thomas | Director | — | I | Series A Preferred Stock | 6,811 | 0.00 | — | 0 | — | ↗ |
| 2016-07-19 | Versant Ventures IV, LLC | 10% Owner | — | D | No securities beneficially held | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-07-19 | Soloway Thomas P | Officer | — | D | Stock Option (right to buy) | 189,819 | 2.77 | 525.8K | 0 | — | ↗ |
| 2016-07-19 | SILVERSTEIN JONATHAN | Director / 10% Owner | — | I | Series C Preferred Stock | 332,766 | 0.00 | — | 0 | — | ↗ |
| 2016-07-19 | Patterson Matthew R | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 201,814 | — | ↗ |
| 2016-07-19 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series A Preferred Stock | 2,511,441 | 0.00 | — | 0 | — | ↗ |
| 2016-07-19 | Holles Natalie C. | Officer | — | D | Stock Option (right to buy) | 189,819 | 2.77 | 525.8K | 0 | — | ↗ |
| 2016-07-19 | Flynn James E | 10% Owner | — | I | Series B Convertible Preferred Stock | 267,998 | 0.00 | — | 0 | — | ↗ |
| 2016-07-19 | 5AM Partners III, LLC | 10% Owner | — | I | Series C Preferred Stock | 6,688 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
22.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Zachary D. Hornby President, Chief Executive Officer, and Director | 638.0K | — | — | 628.4K | 333.4K | 3.5K | 1.60M | 39.19% | ↗ |
| 2 | 2025 | Robert Doebele, M.D., Ph.D. Chief Medical Officer | 458.5K | — | — | 333.0K | 183.3K | 3.5K | 978.3K | 34.04% | ↗ |
| 3 | 2025 | Christian Hassig, Ph.D. Chief Scientific Officer | 478.3K | — | — | 202.4K | 191.2K | 3.5K | 875.4K | 23.12% | ↗ |
| 4 | 2024 | Zachary D. Hornby President, Chief Executive Officer, and Director | 594.6K | — | — | 5.18M | 281.6K | 3.5K | 6.05M | 85.47% | ↗ |
| 5 | 2024 | Christian Hassig, Ph.D. Chief Scientific Officer | 453.1K | — | — | 1.54M | 158.3K | 3.5K | 2.16M | 71.48% | ↗ |
| 6 | 2024 | Klaus Wagner, M.D., Ph.D. Former Chief Medical Officer | 491.8K | — | — | 1.35M | — | — | 1.85M | 73.35% | ↗ |
| 7 | 2024 | Jami Rubin Former Chief Financial Officer | 354.1K | — | — | 1.03M | — | 352.2K | 1.74M | 59.43% | ↗ |
| 8 | 2024 | Neil Abdollahian Former Chief Business Officer | 403.7K | — | — | 740.6K | — | 3.5K | 1.15M | 64.53% | ↗ |
| 9 | 2023 | Zachary D. Hornby President, Chief Executive Officer, and Director | 495.0K | — | — | 1.65M | 222.8K | 3.3K | 2.37M | 69.61% | ↗ |
| 10 | 2023 | Klaus Wagner, M.D., Ph.D. Former Chief Medical Officer | 465.8K | — | — | 363.6K | 163.0K | 3.3K | 995.8K | 36.51% | ↗ |
| 11 | 2023 | Christian Hassig, Ph.D. Chief Scientific Officer | 415.0K | — | — | 340.0K | 145.3K | 3.3K | 903.5K | 37.63% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zachary Hornby | Chief Executive Officer, President & Director | 974.9K | male |
| Robert C. Doebele | Chief Medical Officer | 690.3K | — |
| Christian Hassig | Chief Scientific Officer | 673.0K | — |
| Amy Berkley | Senior Vice President of Program Team | — | female |
| Meredith Wesley | Chief Human Resources Officer | — | female |
| Jessica Oien | Chief Legal Officer & Corporate Secretary | — | female |
| David Hinkle | Senior Vice President of Finance, Controller & Corporate Treasurer | — | male |
| James L. Freddo | Interim Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BOLD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
